Organization
Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany
1 abstract
Abstract
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).Org: NSABP Foundation and UPMC Hillman Cancer Center, Pittsburgh, PA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany, Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA,